脳血管疾患治療市場：治療モダリティ、製品タイプ、疾患タイプ、エンドユーザー別-2024-2030年の世界予測

脳血管疾患治療市場規模は2023年に51億2,000万米ドルと推定され、2024年には54億米ドルに達し、CAGR 5.76％で2030年には75億9,000万米ドルに達すると予測されます。

脳血管疾患には、脳とその血管の脳循環に影響を及ぼすさまざまな疾患が含まれます。特に、脳卒中、一過性脳虚血発作（TIA）、動脈瘤、血管奇形などの疾患が含まれます。脳血管疾患の治療は多面的であり、リスクのある人の発症を予防したり、急性の症状に対処したり、診断後の長期的な影響を管理したりすることを目的としています。治療法は、特定の病態、その重症度、患者の全体的な健康状態によって大きく異なります。具体的な治療戦略の選択は、患者の病歴、脳血管疾患の種類と重症度、ヘルスケアチームの専門知識を含む総合的なアプローチによって決まる。脳卒中や動脈瘤などの脳血管疾患に罹患しやすい高齢化人口の世界の増加と、神経血管ケアにおける医療費の増加が、脳血管疾患治療市場の拡大を後押ししています。しかし、新興国市場では治療や手術の費用が高く、高度なヘルスケア施設へのアクセスが限られていることが市場拡大を妨げる主な要因となっています。医学の進歩は脳血管疾患治療の展望を進化させ続けており、患者にとってより効果的で個別化された選択肢が今後期待されます。

治療様式：低侵襲性による血管内治療の採用拡大

血管内治療法は、動脈瘤、動静脈奇形（AVM）、急性虚血性脳卒中などの病態に対処するための低侵襲技術を活用した脳血管疾患治療の最前線のアプローチです。この方法には主に血管形成術、ステント留置術、塞栓術などの技術が含まれます。血管内治療は，従来の手術と比較して回復に要する時間が短く，合併症のリスクが低いという点で特に有利です。内科的管理は脳血管疾患の治療の基礎であり、薬物的介入によって症状をコントロールし、疾患の進行を予防することに重点を置いています。この治療法には、血栓形成を予防する抗凝固薬や抗血小板薬、血圧をコントロールする降圧薬、虚血性脳卒中などのコレステロール値を低下させるスタチン系薬剤の投与が含まれ、組織プラスミノーゲンアクチベーター（tPA）を含む薬剤は、症状発現後特定の時間内に投与されれば、脳卒中の原因となる血栓を溶解するために使用されます。内科的管理は、将来の脳血管障害のリスクを最小限に抑え、関連する危険因子を管理し、症状を緩和して患者のQOLを改善することを目的としています。外科的介入は、脳血管疾患が血管内治療や内科的管理だけでは十分に管理できない場合に行われます。この治療法には、頸動脈内膜剥離術（CEA）のような手技が含まれます。CEAでは、頸動脈狭窄が著明な患者の脳卒中予防のために頸動脈からプラークを外科的に除去したり、動脈瘤に対して外科的にクリッピングやコイリングを行ったりします。これらの治療法は他の治療法よりも侵襲的でリスクが高いが、救命につながる可能性があり、重篤な合併症や死亡のリスクが高い病態の管理には不可欠です。

エンドユーザー病院や手術センターにおける脳血管疾患治療のニーズの増加

外来手術センターでは、脳血管疾患の治療は侵襲的な外科手術よりも診断、管理、経過観察に主眼が置かれています。このようなセンターでは、入院せずに継続的な治療や監視を必要とする患者が利用しやすくなっています。サービスには、抗凝固薬や抗血小板薬などの薬剤の投与、症状の進行を防ぐためのモニタリング、リハビリテーションを支援し将来の脳血管障害のリスクを減らすための生活習慣のカウンセリングなどが含まれます。病院や外科センターは、脳血管疾患、特に急性期や重症の症例を治療する上で非常に重要です。これらの施設では、高度な診断検査、緊急介入、頸動脈内膜剥離術、ステント留置術、動脈瘤クリッピング術などの外科手術を行うことができます。患者の回復を確実にし、長期的な障害を最小限に抑えるために、術後すぐのケアや集中的なリハビリテーション・サービスも提供されます。さらに、これらのセンターでは、神経科医、外科医、セラピストを含む集学的治療をコーディネートし、患者の状態のあらゆる側面に対処しています。患者の治療には直接関与しないが、研究室や学術機関は脳血管疾患の新しい治療法の開発に大きく貢献しています。これらの施設では、疾患の病態生理学を理解するための基礎研究および臨床研究が行われ、新しい治療標的の発見につながっています。さらに、新規薬剤、機器、治療プロトコルの安全性と有効性を試験する臨床試験の責任も担っています。これらの研究から得られた知見は、既存の治療アプローチを強化するのに役立ち、患者の転帰を改善する革新的な解決策を提供する可能性があります。

地域別の洞察

南北アメリカの脳血管疾患治療市場は、先進的なヘルスケアインフラと、脳卒中や動脈瘤などの脳血管疾患に対する高い認知度を特徴としています。米国は研究開発投資が活発で、製薬企業や医療機器企業が存在感を示し、政府の政策も後押ししています。米国では、非侵襲的治療や個別化医療への動向が顕著です。成長要因としては、高齢化、高血圧や糖尿病の蔓延、不健康な生活習慣の定着などが挙げられます。アジア太平洋地域は、医療費の増加、脳卒中やその他の脳血管疾患に対する意識の高まり、医療インフラの改善などを背景に、脳血管疾患治療市場が急成長しています。特に中国やインドなどの国々は高齢化人口が多く、重要な市場です。手ごろな価格で利用しやすい治療法への革新と、医療制度を強化する政府の取り組みが、アジア太平洋地域における脳血管疾患治療市場の成長を促進すると予想されます。EMEA地域は脳血管疾患治療において多様な市場環境を示しており、欧州はその研究開発活動とヘルスケア支出により重要な市場となっています。高齢化とライフスタイルが欧州における脳血管疾患の有病率に影響を与えています。中東・アフリカの脳血管疾患治療市場は、ヘルスケア投資の増加と医療へのアクセスの改善により拡大しています。これらの地域における市場拡大には、革新的な治療法と政府の取り組みが不可欠です。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、脳血管疾患治療市場の評価において極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、脳血管疾患治療市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.脳血管疾患治療市場の市場規模および予測は？

2.脳血管疾患治療市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.脳血管疾患治療市場の技術動向と規制枠組みは？

4.脳血管疾患治療市場における主要ベンダーの市場シェアは？

5.脳血管疾患治療市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 脳血管疾患に関する意識の高まりと早期スクリーニングの重要性
    • 世界的に高齢化が進み、ヘルスケア費も増加している
  • 抑制要因
    • 脳血管治療の高額な費用
  • 機会
    • 神経血管ケアにおける実質的な研究開発の取り組み
    • 脳血管疾患治療に用いられる機器の進歩
  • 課題
    • 副作用のリスクと熟練した専門家の不足
• 市場セグメンテーション分析
  • 治療法：低侵襲性のため血管内治療の採用が増加
  • エンドユーザー：病院や外科センターにおける脳血管疾患治療の需要増加
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 脳血管疾患治療市場治療法別

• 血管内手術
• 医療管理
• 外科的介入

第7章 脳血管疾患治療市場：製品別

• デバイス
• 薬物治療

第8章 脳血管疾患治療市場：疾患タイプ別

• 出血性脳卒中
• 虚血性脳卒中
• 一過性脳虚血発作（TIA）

第9章 脳血管疾患治療市場：エンドユーザー別

• 外来診療センター
• 病院と外科センター
• 調査室および学術機関

第10章 南北アメリカの脳血管疾患治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の脳血管疾患治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの脳血管疾患治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • セレノバス社、急性虚血性脳卒中患者の血行再建用中間カテーテル「セレグライド 71」を発売
  • エンゼン・バイオサイエンス、血管新生性加齢黄斑変性症（AMD）の治療薬ラニビズマブのバイオシミラーを発売
  • クーパーとインスピラが提携し、南ニュージャージー州で神経科学ケアを拡大
• 戦略分析と提言

第14章 競争力のあるポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. CEREBROVASCULAR DISEASES TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. CEREBROVASCULAR DISEASES TREATMENT MARKET DYNAMICS
• FIGURE 7. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 18. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. CEREBROVASCULAR DISEASES TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 24. CEREBROVASCULAR DISEASES TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CEREBROVASCULAR DISEASES TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY MEDICAL MANAGEMENT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY MEDICAL MANAGEMENT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CAROTID STENTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CAROTID STENTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CEREBRAL BALLOON ANGIOPLASTY AND STENTING SYSTEMS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CEREBRAL BALLOON ANGIOPLASTY AND STENTING SYSTEMS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CLOT RETRIEVAL DEVICES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CLOT RETRIEVAL DEVICES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COIL EMBOLIZATION DEVICES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COIL EMBOLIZATION DEVICES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION SYSTEMS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION SYSTEMS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY FLOW DIVERTER DEVICES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY FLOW DIVERTER DEVICES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY INTRACRANIAL STENTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY INTRACRANIAL STENTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ANTIPLATELET DRUGS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ANTIPLATELET DRUGS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CHOLESTEROL-LOWERING DRUGS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CHOLESTEROL-LOWERING DRUGS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TRANSIENT ISCHEMIC ATTACK (TIA), BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TRANSIENT ISCHEMIC ATTACK (TIA), BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 59. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 60. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 61. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY HOSPITALS & SURGICAL CENTERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 62. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY HOSPITALS & SURGICAL CENTERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 63. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 64. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 65. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
• TABLE 66. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
• TABLE 67. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
• TABLE 68. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
• TABLE 69. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
• TABLE 70. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
• TABLE 71. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
• TABLE 72. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
• TABLE 73. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 74. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 75. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 76. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 77. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 78. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 79. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
• TABLE 80. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
• TABLE 81. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
• TABLE 82. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
• TABLE 83. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
• TABLE 84. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
• TABLE 85. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
• TABLE 86. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
• TABLE 87. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 88. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 89. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 90. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 91. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
• TABLE 92. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
• TABLE 93. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
• TABLE 94. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
• TABLE 95. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
• TABLE 96. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
• TABLE 97. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
• TABLE 98. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
• TABLE 99. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 100. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 101. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 102. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 103. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
• TABLE 104. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
• TABLE 105. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
• TABLE 106. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
• TABLE 107. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
• TABLE 108. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
• TABLE 109. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
• TABLE 110. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
• TABLE 111. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 112. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 113. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 114. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 115. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
• TABLE 116. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
• TABLE 117. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
• TABLE 118. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
• TABLE 119. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
• TABLE 120. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
• TABLE 121. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
• TABLE 122. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
• TABLE 123. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 124. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 125. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 126. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 127. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
• TABLE 128. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
• TABLE 129. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
• TABLE 130. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
• TABLE 131. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
• TABLE 132. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
• TABLE 133. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
• TABLE 134. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
• TABLE 135. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 136. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 137. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 138. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 139. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 140. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 141. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
• TABLE 142. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
• TABLE 143. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
• TABLE 144. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
• TABLE 145. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
• TABLE 146. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
• TABLE 147. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
• TABLE 148. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
• TABLE 149. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 150. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 151. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 152. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 153. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 154. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 155. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
• TABLE 156. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
• TABLE 157. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
• TABLE 158. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
• TABLE 159. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
• TABLE 160. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
• TABLE 161. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
• TABLE 162. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
• TABLE 163. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 164. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 165. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 166. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 167. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
• TABLE 168. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
• TABLE 169. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
• TABLE 170. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
• TABLE 171. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
• TABLE 172. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
• TABLE 173. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
• TABLE 174. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
• TABLE 175. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 176. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 177. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 178. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 179. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
• TABLE 180. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
• TABLE 181. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
• TABLE 182. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
• TABLE 183. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
• TABLE 184. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
• TABLE 185. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
• TABLE 186. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
• TABLE 187. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 188. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 189. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 190. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 191. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
• TABLE 192. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
• TABLE 193. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
• TABLE 194. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
• TABLE 195. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
• TABLE 196. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
• TABLE 197. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
• TABLE 198. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
• TABLE 199. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 200. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 201. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 202. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 203. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
• TABLE 204. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
• TABLE 205. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
• TABLE 206. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
• TABLE 207. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
• TABLE 208. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
• TABLE 209. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
• TABLE 210. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
• TABLE 211. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 212. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 213. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 214. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 215. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
• TABLE 216. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
• TABLE 217. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
• TABLE 218. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
• TABLE 219. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
• TABLE 220. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
• TABLE 221. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
• TABLE 222. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
• TABLE 223. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 224. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 225. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 226. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 227. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
• TABLE 228. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
• TABLE 229. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
• TABLE 230. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
• TABLE 231. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
• TABLE 232. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
• TABLE 233. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
• TABLE 234. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
• TABLE 235. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 236. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 237. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 238. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 239. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
• TABLE 240. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
• TABLE 241. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
• TABLE 242. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
• TABLE 243. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
• TABLE 244. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
• TABLE 245. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
• TABLE 246. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
• TABLE 247. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 248. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 249. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 250. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 251. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
• TABLE 252. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
• TABLE 253. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
• TABLE 254. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
• TABLE 255. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
• TABLE 256. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
• TABLE 257. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
• TABLE 258. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
• TABLE 259. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 260. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 261. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 262. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 263. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
• TABLE 264. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
• TABLE 265. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
• TABLE 266. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
• TABLE 267. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
• TABLE 268. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
• TABLE 269. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
• TABLE 270. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
• TABLE 271. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 272. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 273. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 274. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 275. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
• TABLE 276. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
• TABLE 277. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
• TABLE 278. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
• TABLE 279. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
• TABLE 280. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
• TABLE 281. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
• TABLE 282. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
• TABLE 283. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 284. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 285. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 286. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 287. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
• TABLE 288. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
• TABLE 289. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
• TABLE 290. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
• TABLE 291. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
• TABLE 292. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
• TABLE 293. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
• TABLE 294. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
• TABLE 295. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
• TABLE 296. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
• TABLE 297. VIETNAM CEREBROVASCULAR DISEAS

[190 Pages Report] The Cerebrovascular Diseases Treatment Market size was estimated at USD 5.12 billion in 2023 and expected to reach USD 5.40 billion in 2024, at a CAGR 5.76% to reach USD 7.59 billion by 2030.

Cerebrovascular diseases encompass a range of conditions that affect the cerebral circulation of the brain and its blood vessels. Most notably, these include diseases such as stroke, transient ischemic attack (TIA), aneurysms, and vascular malformations. Treatment for cerebrovascular diseases is multifaceted, designed to either prevent the onset of these conditions in at-risk individuals or to address acute conditions and manage long-term effects post-diagnosis. Treatment modalities vary widely based on the specific condition, its severity, and the patient's overall health. The selection of specific treatment strategies depends on an integrated approach involving the patient's medical history, the type and severity of the cerebrovascular disease, and the expertise of the healthcare team. The rising aging population globally, which is more susceptible to cerebrovascular diseases such as strokes and aneurysms, and the increasing healthcare expenditures in neurovascular care drive the cerebrovascular diseases treatment market expansion. However, the high cost of treatments and surgeries and limited access to the advanced healthcare facilities in developing regions are key factors hindering the market growth. Advances in medical science continue to evolve the landscape of cerebrovascular disease treatment, promising more effective and personalized options for patients moving forward.

Treatment Modality: Growing adoption of endovascular procedures owing to their minimally invasive nature

Endovascular procedures represent a forefront approach to treating cerebrovascular diseases, leveraging minimally invasive techniques to address conditions such as aneurysms, arteriovenous malformations (AVMs), and acute ischemic strokes. This modality primarily includes techniques such as angioplasty, stenting, and embolization. Endovascular procedures are particularly advantageous due to their minimized recovery times and lower risk of complications compared to traditional surgery. Medical management is a cornerstone in treating cerebrovascular diseases, focusing on controlling symptoms and preventing disease progression through pharmaceutical interventions. This modality includes the administration of anticoagulants and antiplatelet agents to prevent clot formation, antihypertensive drugs to control blood pressure, and statins to reduce cholesterol levels for conditions such as ischemic stroke, medications including tissue plasminogen activator (tPA) may be used to dissolve the clot causing the stroke if administered within a specific time window after symptom onset. Medical management aims to minimize the risk of future cerebrovascular events, manage associated risk factors, and provide symptomatic relief, improving patients' quality of life. Surgical intervention is utilized in cases where cerebrovascular diseases cannot be adequately managed through endovascular procedures or medical management alone. This treatment modality may involve procedures such as carotid endarterectomy (CEA), where plaque is surgically removed from the carotid artery for preventing stroke in patients with significant carotid artery stenosis or surgical clipping and coiling for aneurysms. Though these interventions are more invasive and carry greater risk than other treatment modalities, they can be life-saving and are critical for managing conditions that pose a high risk of serious complications or death.

End-user: Increasing need for cerebrovascular diseases treatment in hospitals and surgical centers

In ambulatory care centers, treatments for cerebrovascular diseases are primarily focused on diagnosis, management, and follow-up care rather than invasive surgical procedures. These centers provide accessibility for patients requiring ongoing treatment or monitoring without hospital admission. Services include administering medications, such as anticoagulants and antiplatelets, monitoring symptoms to prevent progression, and lifestyle counseling to support rehabilitation and reduce the risk of future cerebrovascular events. Hospitals and surgical centers are critical in treating cerebrovascular diseases, especially acute and severe cases. These facilities can perform advanced diagnostic tests, emergency interventions, and surgical procedures such as carotid endarterectomy, stenting, and aneurysm clipping. Immediate post-operative care and intensive rehabilitation services are also provided to ensure patient recovery and minimize long-term disabilities. Additionally, these centers coordinate multidisciplinary care involving neurologists, surgeons, and therapists to address all aspects of the patient's condition. While not directly involved in patient care, research laboratories, and academic institutes significantly contribute to developing new treatments for cerebrovascular diseases. These establishments conduct fundamental and clinical research to understand the pathophysiology of diseases, leading to the discovery of novel therapeutic targets. Furthermore, they are responsible for the clinical trials that test the safety and efficacy of novel drugs, devices, and treatment protocols. Insights gained from these studies aid in enhancing existing treatment approaches and potentially offer innovative solutions to improve patient outcomes.

Regional Insights

The market for cerebrovascular disease treatment in the Americas is characterized by advanced healthcare infrastructure and a high degree of awareness about cerebrovascular diseases such as stroke and aneurysms. The United States has robust R&D investments, a strong presence of pharmaceutical and medical device companies, and supportive government policies. The American region showcases a trend towards non-invasive procedures and personalized medicine. Growth factors include the aging population, the prevalence of hypertension and diabetes, and the adoption of unhealthy lifestyle habits. The Asia-Pacific region presents a rapidly growing cerebrovascular disease treatment market driven by increasing healthcare expenditure, rising awareness about stroke and other cerebrovascular conditions, and improving healthcare infrastructure. The countries such as China and India are particularly significant markets with large aging populations. Innovations in affordable and accessible treatments and governmental efforts to enhance healthcare systems are expected to propel cerebrovascular disease treatment market growth in the Asia-Pacific region. The EMEA region exhibits a diverse market landscape for cerebrovascular disease treatment, with Europe being a significant market due to its research and development activities and healthcare spending. An aging population and lifestyle factors influence the prevalence of cerebrovascular diseases in Europe. The cerebrovascular diseases treatment market in the Middle East and Africa is expanding, driven by increasing healthcare investments and improving access to care. Innovative treatments and government initiatives are crucial for market expansion in these regions.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cerebrovascular Diseases Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cerebrovascular Diseases Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cerebrovascular Diseases Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca, AstraZeneca plc, Bayer AG, BIOGEN INC., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Daiichi Sankyo Co. Ltd., GE HealthCare Technologies Inc., Genentech, Inc., Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Medtronic plc, Merck & Co., Inc., Penumbra, Inc., Pfizer Inc., Sangamo Therapeutics, Inc., Sanofi SA, Siemens Healthineers AG, Sihuan Pharmaceutical Holdings Group Ltd., Takeda Pharmaceutical Co. Ltd., and United Therapeutics Corp..

Market Segmentation & Coverage

This research report categorizes the Cerebrovascular Diseases Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Treatment Modality
  • Endovascular Procedures
  • Medical Management
  • Surgical Intervention

• Products
  • Devices
    • Carotid Stents
    • Cerebral Balloon Angioplasty and Stenting Systems
    • Clot Retrieval Devices
    • Coil Embolization Devices
    • Embolic Protection Systems
    • Flow Diverter Devices
    • Intracranial Stents

• Drug Medication
  • Anticoagulants
  • Antihypertensive Drugs
  • Antiplatelet Drugs
  • Cholesterol-lowering Drugs
  • Thrombolytics
• Disease Type
  • Hemorrhagic Stroke
  • Ischemic Stroke
  • Transient Ischemic Attack (TIA)

• End-user
  • Ambulatory Care Centers
  • Hospitals & Surgical Centers
  • Research Laboratories & Academic Institutes

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cerebrovascular Diseases Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cerebrovascular Diseases Treatment Market?

3. What are the technology trends and regulatory frameworks in the Cerebrovascular Diseases Treatment Market?

4. What is the market share of the leading vendors in the Cerebrovascular Diseases Treatment Market?

5. Which modes and strategic moves are suitable for entering the Cerebrovascular Diseases Treatment Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing awareness regarding cerebrovascular diseases and the importance of early screening
    • 5.1.1.2. The rising aging population globally and the increasing healthcare expenditures
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of cerebrovascular treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Substantial R&D initiatives in neurovascular care
    • 5.1.3.2. Advancements in devices used for cerebrovascular disease treatment
  • 5.1.4. Challenges
    • 5.1.4.1. Risk of side effects and lack of skilled professional
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment Modality: Growing adoption of endovascular procedures owing to their minimally invasive nature
  • 5.2.2. End-user: Increasing need for cerebrovascular diseases treatment in hospitals and surgical centers
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Cerebrovascular Diseases Treatment Market, by Treatment Modality

• 6.1. Introduction
• 6.2. Endovascular Procedures
• 6.3. Medical Management
• 6.4. Surgical Intervention

7. Cerebrovascular Diseases Treatment Market, by Products

• 7.1. Introduction
• 7.2. Devices
• 7.3. Drug Medication

8. Cerebrovascular Diseases Treatment Market, by Disease Type

• 8.1. Introduction
• 8.2. Hemorrhagic Stroke
• 8.3. Ischemic Stroke
• 8.4. Transient Ischemic Attack (TIA)

9. Cerebrovascular Diseases Treatment Market, by End-user

• 9.1. Introduction
• 9.2. Ambulatory Care Centers
• 9.3. Hospitals & Surgical Centers
• 9.4. Research Laboratories & Academic Institutes

10. Americas Cerebrovascular Diseases Treatment Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Cerebrovascular Diseases Treatment Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Cerebrovascular Diseases Treatment Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Cerenovus Launched Cereglide 71 Intermediate Catheter for Revascularization in Patients with Acute Ischemic Stroke
  • 13.3.2. Enzene Biosciences Launched Biosimilar to Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration (AMD)
  • 13.3.3. Cooper And Inspira Partner to Expand Neuroscience Care In South Jersey
• 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

• 14.1. Key Company Profiles
• 14.2. Key Product Portfolio